SCHEMBL6419474

SCHEMBL6419474

NC(CS(=O)(=O)O)c1cccc(Oc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 1/20 0.45
EPAS1 Q99814 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
AR P10275 1/20 0.42
ESR2 Q92731 1/20 0.42
PNMT P11086 1/20 0.42
KIF11 P52732 1/20 0.41
PPARG P37231 4/20 0.41
PPARA Q07869 1/20 0.41
POLB P06746 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422777 0.84 PTGS1 (0.50) FDFT1KDM4EALDH1A1MEN1KMT2A
SCHEMBL7090184 0.81 KMT2A (0.56) KDM4EPNMTPPARGPPARAPOLB
SCHEMBL6831085 0.81 KMT2A (0.56) KDM4EPNMTPPARGPPARAPOLB
SCHEMBL7090175 0.81 KMT2A (0.56) KDM4EPNMTPPARGPPARAPOLB
Hydrochloric Acid SCHEMBL7090826 0.80 KMT2A (0.55) KDM4EPNMTPPARGPPARAPOLB
Hydrochloric Acid SCHEMBL7090645 0.80 KMT2A (0.55) KDM4EPNMTPPARGPPARAPOLB
SCHEMBL6034137 0.80 FNTA (0.44) FDFT1PGRPPARGPPARALTA4H
SCHEMBL6034129 0.80 HTT (0.48) ALDH1A1MEN1HTTKMT2ASMN1; SMN2
SCHEMBL6420384 0.79 FNTA (0.47) FDFT1PGRKMT2ASMN1; SMN2LTA4H
SCHEMBL9074029 0.75 PNMT (0.75) KDM4EPNMTPPARGPPARAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases APP, PSEN1, PSEN2 FDFT1 608/4885EPAS1 3622/4885KDM4E 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.